Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Operating Leases (2022 - 2025)

PAVmed has reported Operating Leases over the past 4 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Operating Leases at $2.2 million for Q4 2025, changed 0.04% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (changed 0.04% YoY), and the annual figure for FY2025 was $2.2 million, changed 0.04%.
  • Operating Leases for Q4 2025 was $2.2 million at PAVmed, up from $1.8 million in the prior quarter.
  • Over the last five years, Operating Leases for PAVM hit a ceiling of $5.2 million in Q1 2023 and a floor of $1.8 million in Q3 2025.
  • Median Operating Leases over the past 4 years was $2.6 million (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 146.1% in 2023 and later plummeted 57.81% in 2025.
  • PAVmed's Operating Leases stood at $3.0 million in 2022, then dropped by 0.9% to $3.0 million in 2023, then dropped by 24.09% to $2.2 million in 2024, then increased by 0.04% to $2.2 million in 2025.
  • The last three reported values for Operating Leases were $2.2 million (Q4 2025), $1.8 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.